Trimble E L, Trimble C L
National Cancer Institute, 6130 Executive Boulevard, Suite 741, MSC 7436, Bethesda, MD 20892-7436, USA.
Curr Treat Options Oncol. 2001 Apr;2(2):103-8. doi: 10.1007/s11864-001-0052-2.
Ovarian tumors of low malignant potential (LMP) differ from epithelial ovarian carcinoma in etiology, molecular biology, and prognosis. LMP tumors are not precursor lesions to ovarian carcinoma. Treatment is primarily surgical. Women found to have an ovarian tumor of LMP should undergo removal of the involved adnexa; surgical staging; and cytoreductive surgery. Women in the reproductive years should be given the option of conservative surgery, preserving the contralateral adnexa and uterus. There is no proven benefit to adjuvant chemotherapy or radiotherapy after primary surgery. In most cases, the diagnosis of an ovarian tumor of LMP conveys good prognosis, with excellent long-term survival.
低恶性潜能(LMP)卵巢肿瘤在病因、分子生物学及预后方面与上皮性卵巢癌不同。LMP肿瘤并非卵巢癌的前驱病变。治疗主要为手术治疗。被发现患有LMP卵巢肿瘤的女性应接受受累附件切除术、手术分期及肿瘤细胞减灭术。处于生育年龄的女性应可选择保留对侧附件和子宫的保守性手术。初次手术后辅助化疗或放疗并无已证实的益处。在大多数情况下,LMP卵巢肿瘤的诊断预示着良好的预后及出色的长期生存率。